Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IV Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020
Top-line results showed that 95% of patients treated with Dysport were revealed from severe glabellar lines with two treatments per year, and for 97% the result of the treatment seemed natural.